In contrast, other studies postulated that myeloma stem cells are characterized by a CD38+ CD138+ CD19- CD45- immunophenotype suggesting that stem cell related markers might undergo dynamic changes or differ between MM patients and the experimental model systems (34, 35). Here, CD19 is linked to plasma cell myeloma.